What Does Ozempic® Cost? A Complete 2025 Price Guide

The Exact List Price of Ozempic® in 2025

Brand Ozempic® (semaglutide 0.5 mg, 1 mg, and 2 mg injection pens) carries a manufacturer list price of roughly $935, $1,050 per 28-day supply in 2025, depending on dose strength and pharmacy. The 2 mg pen, introduced in 2022 for patients who need tighter glycemic control, sits at the top of that range. These figures reflect Average Wholesale Price (AWP), which is the starting point pharmacies use before insurance negotiation.

Actual cash prices at retail pharmacies vary. GoodRx data as of January 2025 shows the 0.5 mg/1 mg pen (2 mg/1.5 mL, 4-dose) at approximately $935, $970 at major chains, while independent pharmacies occasionally price slightly lower. The FDA's approved prescribing information for Ozempic® confirms dosing begins at 0.25 mg weekly for four weeks, titrating to 0.5 mg, then up to 2 mg as needed for glycemic targets. [1]

Why the Price Is So High

Novo Nordisk sets U.S. List prices substantially above international equivalents. A 2023 JAMA Internal Medicine analysis found U.S. Semaglutide list prices were roughly eight times higher than prices in Canada and Germany. [2] That gap reflects the U.S. System of rebate negotiation between manufacturers and pharmacy benefit managers, meaning the net price insurers actually pay is lower, but the uninsured patient pays list price.

How Pharmacy Prices Differ by Dose

| Pen Strength | Doses per Pen | Approximate AWP (2025) | |---|---|---| | 0.25 mg / 0.5 mg (starter) | 4 injections | ~$935 | | 1 mg | 4 injections | ~$970 | | 2 mg | 4 injections | ~$1,050 |

One pen covers roughly four weeks of once-weekly dosing. Most patients spend several months at each dose level before reaching their maintenance dose, so early months may cost less per pen but require the same prescription frequency. [1]

Does Insurance Cover Ozempic®?

Insurance coverage depends almost entirely on the diagnosis code attached to the prescription. Ozempic® is FDA-approved for type 2 diabetes (T2D) and cardiovascular risk reduction in adults with T2D and established cardiovascular disease, not for weight loss. [1] Wegovy® is the FDA-approved semaglutide formulation for chronic weight management. This distinction matters enormously for coverage.

Coverage for Type 2 Diabetes

Most commercial health plans cover Ozempic® for T2D with prior authorization. The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents in patients with T2D who have atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease, listing semaglutide specifically. [3] When prescribed on-label with a T2D diagnosis, employer-sponsored plans typically place Ozempic® on Tier 3 with a copay of $30, $150/month after prior authorization.

Coverage for Weight Loss

This is where coverage collapses for most patients. The Treat and Reduce Obesity Act, introduced repeatedly in Congress, has not yet passed into law as of January 2025, meaning Medicare Part D plans are legally prohibited from covering weight-loss drugs. [4] Medicaid coverage varies by state, with fewer than half of state programs covering any GLP-1 agent for obesity as of 2024. [5] Commercial insurers covering Wegovy® for obesity often still reject Ozempic® for that indication because it is not labeled for chronic weight management.

Prior Authorization Requirements

Most plans require documentation of a hemoglobin A1c of 7.0% or higher, failure of at least one prior oral agent (usually metformin), and a confirmed T2D diagnosis from a prescribing clinician. The American Association of Clinical Endocrinology (AACE) 2023 guidelines recommend GLP-1 receptor agonists as preferred second-line agents after metformin in patients with T2D and obesity, which supports prior authorization approval in most cases. [6]

Novo Nordisk Savings Programs: Real Numbers

Novo Nordisk offers two savings paths depending on insurance status.

Ozempic® Savings Card (Commercially Insured)

Eligible commercially insured patients can pay as little as $25 per month through the Novo Nordisk savings card. The card is available at NovoCare.com and applies to patients with private insurance who meet income and coverage criteria. The card does not apply to government-funded insurance including Medicare, Medicaid, TRICARE, or VA coverage. [7]

NovoCare Patient Assistance Program (Uninsured / Underinsured)

Uninsured patients or those whose insurance does not cover Ozempic® may qualify for the NovoCare Patient Assistance Program, which provides free medication to patients meeting income guidelines (generally at or below 400% of the federal poverty level). Patients who do not qualify for free medication but are uninsured can access a separate savings offer capping cost at $199 per month. [7]

Eligibility Checklist

• Must have a valid U.S. Prescription
• Must not be enrolled in a federal health insurance program
• Income documentation required for the full patient assistance program
• The savings card resets annually; patients must re-enroll each calendar year

Compounded Semaglutide: Costs and Context

During the FDA-declared shortage of semaglutide (which ran from 2022 through early 2025), 503A and 503B compounding pharmacies were permitted to produce compounded semaglutide. Cash prices ranged from $150, $500 per month depending on dose, pharmacy, and whether the telehealth consultation fee was bundled.

FDA Shortage Status and Compounding Rules

The FDA removed semaglutide from its drug shortage database in early 2025, which triggered restrictions on compounding. Under 21 U.S.C. § 503A and § 503B, compounding of a drug that is not on the shortage list is generally prohibited unless the compounded version differs from the commercially available product in a clinically meaningful way. [8] The FDA issued guidance in February 2025 clarifying that 503B outsourcing facilities must cease compounding semaglutide that is essentially a copy of Ozempic® or Wegovy®. [8] Patients currently using compounded semaglutide should confirm their pharmacy's legal status with their prescriber.

Quality and Safety Considerations

Compounded products are not FDA-approved and have not undergone the same manufacturing inspections as brand products. A 2023 ISMP report documented cases of dosing errors and contamination associated with improperly compounded semaglutide. [9] The FDA has issued multiple warnings about compounded semaglutide products containing semaglutide sodium or acetate salt forms rather than the active base used in Ozempic® and Wegovy®. [8]

When Compounded Semaglutide May Still Be Appropriate

A 503A pharmacy may compound semaglutide for a specific patient if a licensed prescriber documents a clinical need that the commercially available product cannot meet, such as an allergy to an excipient. This is a narrow exception and requires explicit prescriber documentation. [8]

How Calibrate Fits Into the Ozempic® Cost Picture

Calibrate was a telehealth weight-loss program that paired GLP-1 prescriptions (including Ozempic® when prescribed off-label for obesity) with lifestyle coaching. Understanding its pricing model helps explain a category of telehealth GLP-1 services.

Calibrate's Fee Structure

Calibrate charged a $199 one-time membership fee plus the ongoing cost of the GLP-1 prescription itself. The prescription cost passed through to the patient's pharmacy, meaning patients with commercial insurance paid their pharmacy copay, while uninsured patients paid cash price or used savings cards. Calibrate did not manufacture or dispense medication; it was a prescription and coaching intermediary.

Calibrate's Current Status

Calibrate significantly scaled back operations in 2023 and 2024 amid broader challenges in the direct-to-consumer GLP-1 market, including insurance denials and drug shortages. Patients who enrolled through Calibrate and were prescribed Ozempic® off-label for obesity frequently faced coverage denials when insurers identified the off-label use. [10] As of early 2025, Calibrate's program is not widely available.

Alternatives to Calibrate

Several telehealth platforms now offer GLP-1 prescriptions with integrated coaching:

• Hims & Hers: offered compounded semaglutide at $199, $299/month during shortage; pivoting to branded products post-shortage
• Ro Body: bundles Wegovy® or tirzepatide prescriptions with metabolic coaching; price varies by insurance
• Noom Med: prescription plus behavioral program; Wegovy® at insurance copay or cash price
• HealthRX: physician-supervised GLP-1 and metabolic programs with ongoing lab monitoring

Each platform passes the FDA-regulated drug cost to the patient separately from program fees. No telehealth platform can reduce the underlying drug cost below what Novo Nordisk or the pharmacy charges unless they are dispensing compounded product from an affiliated pharmacy.

Total Monthly Cost Scenarios: Real Patient Examples

The following framework covers the four most common patient situations in 2025.

Scenario 1: Commercial Insurance, T2D Diagnosis

A 52-year-old with T2D and commercial employer insurance obtains prior authorization for Ozempic® 0.5 mg. With the Novo Nordisk savings card stacked on the insurance Tier 3 copay, this patient pays $25, $50/month. Total annual cost: approximately $300, $600.

Scenario 2: Commercial Insurance, Obesity Only (No T2D)

A 38-year-old with BMI of 34 and no T2D diagnosis seeks Ozempic® for weight loss. The plan denies coverage because Ozempic® is not approved for obesity and the plan does not cover Wegovy®. The prescriber pivots to Wegovy®; the plan still denies. Cash price for Wegovy® 2.4 mg: approximately $1,350/month. With Novo Nordisk's Wegovy® savings offer (commercially insured), cost may drop to $0 for the first month, then $25/month if insurer approves, or $499/month uninsured cap. STEP-1 (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, supporting the clinical argument for coverage. [11]

Scenario 3: Medicare, Any Indication for Weight Loss

A 67-year-old with obesity and no T2D asks about Ozempic® through Medicare Part D. Medicare Part D currently cannot cover weight-loss drugs by statute. If this patient also has T2D, Ozempic® may be covered for glycemic control. The SUSTAIN-6 trial (N=3,297) showed semaglutide 0.5 mg and 1 mg reduced major adverse cardiovascular events by 26% versus placebo (HR 0.74, 95% CI 0.58 to 0.95, P<0.001 for noninferiority), supporting coverage for cardiovascular risk reduction in Medicare patients with T2D and established CVD. [12]

Scenario 4: Uninsured, Cash Pay

An uninsured 44-year-old with T2D pays full cash price. Options in order of cost:

1. NovoCare Patient Assistance Program (free if income-eligible)
2. NovoCare savings cap ($199/month if not income-eligible)
3. GoodRx coupon at retail pharmacy (~$900, $950/month)
4. Compounded semaglutide from a licensed 503B pharmacy ($150, $400/month, subject to current legality)

GLP-1 Cost-Effectiveness: What the Evidence Shows

Cost is not just an out-of-pocket question. Payers and health economists have studied whether Ozempic® and related GLP-1 agents save money over time by reducing cardiovascular events, hospitalizations, and complications of diabetes and obesity.

Cardiovascular Outcomes Data

The SUSTAIN-6 trial demonstrated a 26% relative risk reduction in major adverse cardiovascular events with semaglutide in high-risk T2D patients. [12] A 2022 NEJM analysis of the SELECT trial pre-specified design (N=17,604) confirmed that semaglutide 2.4 mg reduced cardiovascular events in adults with obesity and established CVD but without diabetes, with results published in 2023 showing a 20% reduction in MACE (HR 0.80, 95% CI 0.72 to 0.90, P<0.001). [13] These outcomes data are the primary argument insurers use to justify coverage for T2D and CVD indications, and the primary argument advocates use to push for obesity coverage expansion.

Kidney Protection

The FLOW trial (N=3,533) showed semaglutide 1 mg reduced the composite kidney endpoint (sustained decline in eGFR, kidney failure, or kidney or cardiovascular death) by 24% versus placebo in patients with T2D and chronic kidney disease (HR 0.76, 95% CI 0.66 to 0.88, P<0.001). [14] The FDA expanded Ozempic®'s label in 2024 to include reduction of kidney disease progression in adults with T2D and chronic kidney disease. [1] This expanded indication may open additional insurance coverage pathways for eligible patients.

Economic Modeling

A 2022 Diabetes Care cost-effectiveness analysis modeled semaglutide 1 mg in T2D patients with high cardiovascular risk and found an incremental cost-effectiveness ratio of approximately $48,000 per quality-adjusted life year (QALY) gained, well below the conventional $100,000/QALY threshold used by U.S. Health economists. [15] For obesity treatment with semaglutide 2.4 mg, a 2023 JAMA Network Open analysis projected cost-effectiveness only if the drug price fell below $7,500/year (roughly $625/month), suggesting current list prices remain above cost-effective thresholds for pure weight-loss indications without comorbidities. [16]

How to Reduce Your Ozempic® Cost: A Step-by-Step Action Plan

Step 1: Confirm the Right Drug for Your Diagnosis

If you have T2D, Ozempic® is on-label. If you have obesity without T2D, ask your prescriber whether Wegovy® or tirzepatide (Zepbound®, FDA-approved for obesity) is the better choice for insurance purposes. Using the right drug for the right indication is the single fastest path to coverage.

Step 2: Request Prior Authorization With Full Documentation

Your prescriber should submit documentation of your A1c (for T2D), BMI, comorbidities (cardiovascular disease, sleep apnea, hypertension, CKD), and prior medication trials. The Obesity Medicine Association recommends documenting at least one comorbidity linked to obesity to strengthen the clinical necessity argument. [17]

Step 3: Appeal Denials

First-level insurance denials are denied on administrative grounds roughly 60% of the time in commercial plans, according to a 2023 KFF analysis. [5] A physician-written letter of medical necessity citing the SUSTAIN-6 or SELECT cardiovascular outcome data reverses denials in a meaningful proportion of cases. Ask your prescriber to include specific trial citations and your individual risk factors.

Step 4: Apply for Manufacturer Savings

Register at NovoCare.com before filling your first prescription. The savings card must be presented at the pharmacy at the time of dispensing; retroactive application is not available at most pharmacies.

Step 5: Explore State Pharmaceutical Assistance Programs

Seventeen states operate pharmaceutical assistance programs that may cover GLP-1 agents for low-income residents regardless of Medicare/Medicaid limitations. Eligibility criteria vary; the National Conference of State Legislatures maintains an updated list. [18]

Side Effects That May Affect Your Cost Calculations

Knowing the most common adverse effects helps you anticipate potential additional costs (antiemetics, dietary adjustments, clinical visits for symptom management).

Gastrointestinal Effects

The SUSTAIN-6 trial reported nausea in 22.5% of semaglutide-treated patients versus 8.6% with placebo. [12] Vomiting occurred in 9.8% versus 3.7%. These effects are dose-dependent and typically peak during titration. The FDA prescribing information recommends slower titration if GI side effects are intolerable. [1]

Gastroparesis Risk

A 2023 JAMA study (N=55,000+ matched patients) found GLP-1 receptor agonist users had a higher incidence of gastroparesis compared with bupropion-naltrexone users (hazard ratio 3.67, 95% CI 1.15 to 11.90). [19] Patients with pre-existing gastroparesis or slow gastric motility should discuss this risk with their prescriber before starting Ozempic®.

Pancreatitis and Thyroid C-Cell Tumors

The Ozempic® prescribing information carries a black-box warning for thyroid C-cell tumors based on rodent data; human causality has not been established. [1] Acute pancreatitis has been reported; patients with a history of pancreatitis should weigh this risk explicitly with their physician. The FDA MedWatch reporting system documents ongoing pharmacovigilance for both signals. [20]